Except: Prescription drug counterfeiters have placed our nation's patients at risk; their criminal actions take advantage of the current patchwork of state laws that could allow venue‐shopping for the best locale in which to expose patients to unsafe and counterfeit prescription drugs.
Excerpt: What is the status of DOC-IG investigative performance? Has it been improving or declining? Has it been affected by controversies and disputes between some current or former DOC law enforcement agents and the DOC-IG management? Has performance been affected by certain personnel practices?; To read the letter, click here.
Excerpt: It is our understanding that the NRC has a track record of producing cost estimates for its requirements on nuclear power reactors that can be egregiously off target from the actual costs of implementing the requirements. To read the letter, click here.
To read EPA's May 15, 2013, response, click here.
Exceprt: Since the week of February 18, 2013, through the last available listing in April 2013, the FDA's Public Calendar has listed Dr. Brenner-Gati as the Acting Deputy Commissioner for Medical Products and Tobacco with no significant meetings. However, the FDA posted on its website the FDA organizational chart approved and signed on March 4, 2013, by the FDA Reorganization Coordinator listing the position of Deputy Commissioner for Medical Products as vacant.
To read the letter to HHS, click here. To read the letter to the following companies, click here.